Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

638 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Janssen PM, Murray JD, Schill KE, Rastogi N, Schultz EJ, Tran T, Raman SV, Rafael-Fortney JA. Janssen PM, et al. Among authors: rastogi n. PLoS One. 2014 Feb 13;9(2):e88360. doi: 10.1371/journal.pone.0088360. eCollection 2014. PLoS One. 2014. PMID: 24551095 Free PMC article.
Claudin-5 levels are reduced from multiple cell types in human failing hearts and are associated with mislocalization of ephrin-B1.
Swager SA, Delfín DA, Rastogi N, Wang H, Canan BD, Fedorov VV, Mohler PJ, Kilic A, Higgins RSD, Ziolo MT, Janssen PML, Rafael-Fortney JA. Swager SA, et al. Among authors: rastogi n. Cardiovasc Pathol. 2015 May-Jun;24(3):160-167. doi: 10.1016/j.carpath.2014.10.006. Epub 2014 Nov 7. Cardiovasc Pathol. 2015. PMID: 25440958 Free PMC article.
The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy.
Lowe J, Wodarcyk AJ, Floyd KT, Rastogi N, Schultz EJ, Swager SA, Chadwick JA, Tran T, Raman SV, Janssen PM, Rafael-Fortney JA. Lowe J, et al. Among authors: rastogi n. J Neuromuscul Dis. 2015;2(3):257-268. doi: 10.3233/JND-150099. Epub 2015 Sep 2. J Neuromuscul Dis. 2015. PMID: 27110493 Free PMC article.
Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
Lowe J, Floyd KT, Rastogi N, Schultz EJ, Chadwick JA, Swager SA, Zins JG, Kadakia FK, Smart S, Gomez-Sanchez EP, Gomez-Sanchez CE, Raman SV, Janssen PM, Rafael-Fortney JA. Lowe J, et al. Among authors: rastogi n. J Neuromuscul Dis. 2016;3(3):395-404. doi: 10.3233/JND-160173. J Neuromuscul Dis. 2016. PMID: 27822449 Free PMC article.
Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.
Lowe J, Kolkhof P, Haupt MJ, Peczkowski KK, Rastogi N, Hauck JS, Kadakia FK, Zins JG, Ciccone PC, Smart S, Sandner P, Raman SV, Janssen PML, Rafael-Fortney JA. Lowe J, et al. Among authors: rastogi n. ESC Heart Fail. 2020 Dec;7(6):3983-3995. doi: 10.1002/ehf2.12996. Epub 2020 Sep 18. ESC Heart Fail. 2020. PMID: 32945624 Free PMC article.
638 results